Bisorcic
Liver-protective and stimulant drug
From Wikipedia, the free encyclopedia
Bisorcic (INN), also known as N2,N5-diacetyl-L-ornithine, is a drug described as a hepatoprotective agent and "psychostimulant" which has been used in France in the treatment of asthenia.[2][3][4][5][1] It is the N2,N5-diacetylated derivative of the amino acid L-ornithine.[6]
| Clinical data | |
|---|---|
| Other names | N2,N5-Diacetyl-L-ornithine; N2,N5-Diacetylornithine; Nα,Nδ-Diacetylornithine |
| Routes of administration | Oral[1] |
| Drug class | Hepatoprotective agent; Psychostimulant[2][1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.049.659 |
| Chemical and physical data | |
| Formula | C9H16N2O4 |
| Molar mass | 216.237 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bisorcic was first described in the literature in 1973 in a German patent.[2] The INN was designated around 1975.[7] The drug was marketed in France by Astyl-Gallier in 1987.[1] It was provided in the form of 200 mg oral capsules and four capsules were taken daily.[1]
L-Ornithine, as the combination drug L-ornithine L-aspartate (LOLA), has been used in the treatment of hepatic encephalopathy and cirrhosis and is likewise described as hepatoprotective.[8][9] It is thought to work by participating in the urea cycle and lowering ammonia levels.[8][9]